Inebilizumab

Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research[1].

Product Specifications

CAS Number

[1299440-37-1]

Product Name Alternative

MEDI-551

UNSPSC

12352203

Target

ADC Antibody; CD19

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/inebilizumab.html

Purity

99.00

Solubility

H2O

Smiles

[Inebilizumab]

Molecular Weight

(150 kDa)

References & Citations

[1]Chen D, et al. Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies. J Clin Med. 2016 Nov 24;5 (12) :107.|[2]Herbst R, et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther. 2010 Oct;335 (1) :213-22.